The role of PRL and PRL receptors (PRLR) in tumor progression and tumorigenesis is well known [31, 32], and several studies have manifested the regulatory involvement of PRLR in medication responsiveness and the prometastatic effect of PRL on breast cancer and other gynecological cancers [33, 34]. The gene discussed is PRL; the disease is female reproductive organ cancer.